Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants

2025-521402-18-00 Protocol NIR-DT-106 Human pharmacology (Phase I) - Other Ended

Start 24 Oct 2025 · End 28 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NIR-DT-106

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Desmoid tumor

Key facts

Sponsor
Springworks Therapeutics Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
24 Oct 2025 → 28 Mar 2026
Decision date (initial)
2025-10-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Desmoid tumor

VersionLevelCodeTermSystem organ class
25.0 LLT 10049444 Fibromatosis 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Springworks Therapeutics Inc.

Sponsor organisation
Springworks Therapeutics Inc.
Address
100 Washington Boulevard
City
Stamford
Postcode
06902-9302
Country
United States

Scientific contact point

Organisation
Springworks Therapeutics Inc.
Contact name
Shina Cheng

Public contact point

Organisation
Springworks Therapeutics Inc.
Contact name
Shina Cheng

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 16 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-10-24 2026-03-27 2025-10-27 2026-02-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-01 Netherlands Acceptable
2025-10-17
2025-10-22
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-29 Netherlands Acceptable
2025-11-06
2025-11-06
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-22 Netherlands Acceptable
2026-01-22
2026-01-23
4 SUBSTANTIAL MODIFICATION SM-3 2026-03-06 Netherlands Acceptable 2026-03-12